Hormone Receptor-Positive Breast Carcinoma

Observed

→ investigated in trials for

Fulvestrantsmall molecule

8 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Letrozolesmall molecule

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Anastrozolesmall molecule

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Exemestanesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tamoxifensmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Elacestrantsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Goserelinother

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Palbociclibsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ribociclibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trastuzumabmonoclonal antibody

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Abexinostatsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Abirateronesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Alpelisibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Aromatase Inhibitor

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Hormone Receptor-Positive Breast Carcinoma studied in …STUDIED_INderived10 of 67show all (up to 200)
→ studied in	NCT06058377Phase 3 · recruiting Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)	—	—	Hormone Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06120283Phase 1 · recruiting BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)	—	—	Hormone Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07391774Phase 3 · recruiting Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)	—	—	Estrogen Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06179303Phase 2 · recruiting Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer · condition mapped CURATED_BROADER · 67 trials mapped (41 active)	—	—	Hormone Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07020117Phase 1 · recruiting A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors · condition mapped ALIAS · 67 trials mapped (41 active)	—	—	Hormone Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04316117Phase 2 · active not recruiting Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)	—	—	Hormone Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03939897Phase 1 · active not recruiting Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer · condition mapped CURATED_BROADER · 67 trials mapped (41 active)	—	—	Hormone Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06671912Phase 3 · suspended Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)	—	—	Estrogen Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07596212Phase 1/Phase 2 · not yet recruiting BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)	—	—	Hormone Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07191717Phase 2 · recruiting Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial · condition mapped CURATED_BROADER · 67 trials mapped (41 active)	—	—	Estrogen Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →

Hormone Receptor-Positive Breast Carcinoma studied in …STUDIED_INderived10 of 67show all (up to 200)

→ studied in

NCT06058377Phase 3 · recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)

—

Observed

→ studied in

NCT06120283Phase 1 · recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)

—

Observed

Estrogen Receptor-Positive Breast Carcinoma

→ studied in

NCT07391774Phase 3 · recruiting

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)

—

Observed

→ studied in

NCT06179303Phase 2 · recruiting

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer · condition mapped CURATED_BROADER · 67 trials mapped (41 active)

—

Observed

→ studied in

NCT07020117Phase 1 · recruiting

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors · condition mapped ALIAS · 67 trials mapped (41 active)

—

Observed

→ studied in

NCT04316117Phase 2 · active not recruiting

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)

—

Observed

→ studied in

NCT03939897Phase 1 · active not recruiting

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer · condition mapped CURATED_BROADER · 67 trials mapped (41 active)

—

Observed

Estrogen Receptor-Positive Breast Carcinoma

→ studied in

NCT06671912Phase 3 · suspended

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)

—

Observed

→ studied in

NCT07596212Phase 1/Phase 2 · not yet recruiting

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder · condition mapped ONTOLOGY_EXACT · 67 trials mapped (41 active)

—

Observed

Estrogen Receptor-Positive Breast Carcinoma

→ studied in

NCT07191717Phase 2 · recruiting

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial · condition mapped CURATED_BROADER · 67 trials mapped (41 active)

—

Observed